Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Immunocore Holdings plc

35 indications, side-by-side phase, drug & LoA

$28.96

+0.34 (+1.19%)

B 62Pipeline Score Fair Value Biotech · Commercial
Market Cap
1.47 B
EPS
-0.55
P/E Ratio
-
Value Trade
18.56 M
SEC Financials
Q1 2026

  • Dilution Risk

    5%

  • Revenue

    106.68 M

  • R&D Expenses

    61.11 M

  • Operating CF

    -13.78 M

  • Total Assets

    1.07 B

  • Total Liabilities

    678.42 M

  • Equity

    393.67 M

  • D/E Ratio

    12,345

0.35 %
Week
-2.4 %
1 Month
-13.24 %
3 Month
-25.98 %
6 Month
-22.35 %
5 Year
-29.68 %
All Time
Cash Data
Healthy

  • Cash Position

    844.90 M

  • Monthly Burn

    4.59 M

  • Runway

    182.9 mo

  • Burn Trend

    Accelerating

  • SEC Filing

    May 6, 2026
Overview
Volume
276.83 K
52 Week Range
27.56 - 40.71
% held by Insiders
0.96 %
% held by Institutions
102.27 %
Enterprise Value
1.06 B
Total Shares
50.83 M
Short %
17.38 %
Float Shares
50.34 M
Company Description
HQ: 90 PARK DRIVE, OXFORDSHIRE, X0...
Employees:524
https://www.immunocore.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
phase 3 data readout example
KIMMTRAK (tebentafusp) metastatic uveal melanoma
Phase 3
—
Biologics
Oncology
KIMMTRAK (tebentafusp) metastatic uveal melanoma
Phase 3
—
Biologics
Oncology
KIMMTRAK (tebentafusp) metastatic uveal melanoma
Phase 3
—
Biologics
Oncology
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
B62
Pipeline Score
$1.8B
Pipeline Value
Fair Value
Valuation Signal
7
Drugs Scored
1.2x
rNPV / MCap
Top 88%
Micro Cap
(rank 110 of 905)
Percentile Rank
Immunocore Holdings plc holds a solid B-grade pipeline (62/100), with $4.5B risk-adjusted pipeline value, led by IMC-S118AI in Type 1 Diabetes (Phase 1).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
IMC-S118AI
Monoclonal antibody		Type 1 DiabetesPhase 1NCT0749312226% $2.0B NOT YET_RECRUITING 154 VERY_FAST C (45) Nov 1, 2030 -LOW
May 26, 2026
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
KIMMTRAK
metastatic uveal melanoma,advanced cutaneous melanoma
Phase 3
2025-08-07
KIMMTRAK
metastatic uveal melanoma,advanced cutaneous melanoma
Phase 3
2025-08-07
KIMMTRAK
metastatic uveal melanoma,advanced cutaneous melanoma
Phase 3
2025-08-07
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in IMCR
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
IMCR
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
IMCR
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
IMCR
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
IMCR Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
IMCR Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-06-180 0.00 0 0 - - - - - -
2026-06-180 0.00 0 0 - - - - - -
2026-06-180 0.00 0 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Immunocore Holdings plc (IMCR) News & Alerts
-
Saturday, June 13, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How IMCR ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
Melanoma #9 of 52 PHASE 3 Tebentafusp
MRK BMY REGN
$10.5B 0.64 CONTENDER
Type 1 Diabetes #14 of 19 PHASE 1 IMC-S118AI
LLY NVO SNY
$3.5B 0 FOLLOWER